News
ProtoKinetix Files for Patent Protection for the Use of AAGP® in Transplant Medicine
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) recently filed for patent protection for a new application of its AAGP® molecule.
During recent
Genprex Regains Compliance with Nasdaq Minimum Bid Price Requirement
Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to
Genprex to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC)
Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to
Genprex to Present at NobleCon16 Investor Conference
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to
The Truth About Mannatech
On February 1, 2020, Mannatech is publishing an objective and fact-based website detailing the science behind their products and the history of their 26-year reign in the direct selling health and
Dover Motorsports, Inc. Reports Results for the Fourth Quarter and Year Ended December 31, 2019
Dover Motorsports, Inc. (NYSE: DVD) today reported its results for the fourth quarter and year ended December 31, 2019.
Our fall NASCAR event weekend, which consisted of a K&N Pro Series East
Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to
Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to
ProtoKinetix Takes Delivery of GMP AAGP® PKX-001 Dedicated for Phase 1 Trial
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) announces that the Company has taken procession of an additional 200 grams of GMP grade PKX-001
Sonoma Pharmaceuticals macht Ernst: Verkauf schafft +500%-Phantasie
Sonoma Pharmaceuticals (WKN: A2PMPH) hat die Investmentbank Maxim Group damit beauftragt, strategische Alternativen für seine US-Dermatologiesparte zu identifizieren. Profis wissen, was das
Dover Motorsports, Inc. Announces Fourth Quarter and Year Ended 2019 Earnings Release Date
Dover Motorsports, Inc. (NYSE: DVD) will report its results for the fourth quarter and year ended December 31, 2019 on the morning of Thursday, January 30, 2020. Commentary from the Company’s
Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly
Cidara: NBC kassiert +136% plus Bonus!
Der No Brainer Club empfahl die Aktie von Cidara Therapeutics (WKN: A14R2R) am 26. September letzten Jahres „stark zu kaufen“. Seitdem steht ein zwischenzeitlicher Kursgewinn von +134% zu Buche
Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to
Novus Therapeutics Provides Update on OP0201
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today provided an update on the
Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the
ProtoKinetix AAGP® Dry Eye Therapy Testing Results
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) announces that ITR Laboratories of Montreal have run multiple tests on eye irritation at maximum
Genprex to Present at Biotech Showcase™ 2020 in San Francisco
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, nonviral proprietary platform designed to deliver tumor suppressor genes to
Cidara und Otonomy: Weitere NBC-Favoriten knallen durch die Decke
Aktien von Cidara Therapeutics (WKN: A14R2R) und Otonomy (WKN: A119VZ) gehörten vergangene Woche mal wieder zu den Gewinnern im Biotech-Sektor. Stehen hier ähnliche Entwicklungen an wie jüngst bei
Mannatech Announces Share Repurchase Program
Mannatech, Incorporated (NASDAQ: MTEX), today announced that its Board of Directors has approved a share repurchase program to acquire up to $1,000,000.00 of its outstanding common stock. The
DropCar and AYRO Announce Signing of Merger Agreement
DropCar, Inc. (Nasdaq: DCAR) (“DropCar”) and privately-held AYRO, Inc. (“AYRO”), an Austin-based company, today jointly announced that they have signed a definitive merger agreement under which, if
ProtoKinetix AAGP® Retinal Cell Replacement Therapy Testing at UBC Completed
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) announces the completion of an in vivo study to assess the effect of AAGP® on the long term survival
IVERIC bio: No Brainer Club feiert +486% in 7 Wochen
Die Aktie von IVERIC bio (WKN: A2PHLF) konnte innerhalb der letzten sieben Wochen um +486% von 0,91 USD auf gestern 5,33 USD im Hoch zulegen. Eine Entwicklung, die im exklusiven No Brainer Club so
Fuel Tech Awarded Air Pollution Control Orders Totaling $2.6 Million
Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control and water treatment in utility and
1347 Property Insurance Holdings Completes Sale of Insurance Operations to FedNat
1347 Property Insurance Holdings, Inc. (Nasdaq: PIH) (the “Company” or “1347 PIH”), today announced the closing of the previously-announced sale of 1347 PIH’s homeowners’ insurance operations (the